Publications

Ribeiro CFidalgo, Rodrigues S, Bastos DCampanella, Fanelli GNicolò, Pakula H, Foiani M, Zadra G, Loda M.  2024.  Blocking lipid synthesis induces DNA damage in prostate cancer and increases cell death caused by PARP inhibition.. Sci Signal. 17(831):eadh1922.

Pakula H, Omar M, Carelli R, Pederzoli F, Fanelli GNicolò, Pannellini T, Socciarelli F, Van Emmenis L, Rodrigues S, Fidalgo-Ribeiro C et al..  2024.  Distinct mesenchymal cell states mediate prostate cancer progression.. Nat Commun. 15(1):363.

Boufaied N, Chetta P, Hallal T, Cacciatore S, Lalli D, Luthold C, Homsy K, Imada EL, Syamala S, Photopoulos C et al..  2024.  Obesogenic High-Fat Diet and MYC Cooperate to Promote Lactate Accumulation and Tumor Microenvironment Remodeling in Prostate Cancer.. Cancer Res. 84(11):1834-1855.

Tamarindo GHenrique, Ribeiro CFidalgo, Silva ADella Torr, Castro A, Caruso ÍPutinhon, Souza FPereira, Taboga SRoberto, Loda M, Góes RMaira.  2024.  The polyunsaturated fatty acid docosahexaenoic affects mitochondrial function in prostate cancer cells.. Cancer Metab. 12(1):24.

Omar M, Xu Z, Rand SB, Alexanderani MK, Salles DC, Valencia I, Schaeffer EM, Robinson BD, Lotan TL, Loda M et al..  2024.  Semi-Supervised, Attention-Based Deep Learning for Predicting TMPRSS2:ERG Fusion Status in Prostate Cancer Using Whole Slide Images.. Mol Cancer Res. 22(4):347-359.

Ma C, Zhou Y, Fanelli GNicolò, Stopsack KH, Fiorentino M, Zadra G, Mucci LA, Loda M, Tyekucheva S, Penney KL.  2023.  The Prostate Stromal Transcriptome in Aggressive and Lethal Prostate Cancer.. Mol Cancer Res. 21(3):253-260.

Pederzoli F, Raffo M, Pakula H, Ravera F, Nuzzo PVitale, Loda M.  2023.  "Stromal cells in prostate cancer pathobiology: friends or foes?". Br J Cancer. 128(6):930-939.

Gao X, Wang Y, Ribeiro CF, Manokaran C, Chang H, Von T, Rodrigues S, Cizmecioglu O, Jia S, Korpal M et al..  2022.  Blocking PI3K p110β Attenuates Development of PTEN-Deficient Castration-Resistant Prostate Cancer.. Mol Cancer Res. 20(5):673-685.

Rosenthal J, Carelli R, Omar M, Brundage D, Halbert E, Nyman J, Hari SN, Van Allen EM, Marchionni L, Umeton R et al..  2022.  Building Tools for Machine Learning and Artificial Intelligence in Cancer Research: Best Practices and a Case Study with the PathML Toolkit for Computational Pathology.. Mol Cancer Res. 20(2):202-206.

Francini E, Fanelli GNicolò, Pederzoli F, Spisak S, Minonne E, Raffo M, Pakula H, Tisza V, Scatena C, Naccarato AGiuseppe et al..  2022.  Circulating Cell-Free DNA in Renal Cell Carcinoma: The New Era of Precision Medicine.. Cancers (Basel). 14(18)

Choi SYC, Ribeiro CFidalgo, Wang Y, Loda M, Plymate SR, Uo T.  2022.  Druggable Metabolic Vulnerabilities Are Exposed and Masked during Progression to Castration Resistant Prostate Cancer.. Biomolecules. 12(11)

Qiu X, Boufaied N, Hallal T, Feit A, de Polo A, Luoma AM, Alahmadi W, Larocque J, Zadra G, Xie Y et al..  2022.  MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targets.. Nat Commun. 13(1):2559.

Gondane A, Girmay S, Helevä A, Pallasaho S, Loda M, Itkonen HM.  2022.  O-GlcNAc transferase couples MRE11 to transcriptionally active chromatin to suppress DNA damage.. J Biomed Sci. 29(1):13.

Davidson SM, Schmidt DR, Heyman JE, O'Brien JP, Liu AC, Israelsen WJ, Dayton TL, Sehgal R, Bronson RT, Freinkman E et al..  2022.  Pyruvate Kinase M1 Suppresses Development and Progression of Prostate Adenocarcinoma.. Cancer Res. 82(13):2403-2416.

Centenera MM, Scott JS, Machiels J, Nassar ZD, Miller DC, Zinonos I, Dehairs J, Burvenich IJG, Zadra G, Chetta PM et al..  2021.  ELOVL5 Is a Critical and Targetable Fatty Acid Elongase in Prostate Cancer.. Cancer Res. 81(7):1704-1718.

Bastos DC, Ribeiro CF, Ahearn T, Nascimento J, Pakula H, Clohessy J, Mucci L, Roberts T, Zanata SM, Zadra G et al..  2021.  Genetic ablation of FASN attenuates the invasive potential of prostate cancer driven by Pten loss.. J Pathol. 253(3):292-303.

Penney KL, Tyekucheva S, Rosenthal J, Fandy HEl, Carelli R, Borgstein S, Zadra G, Fanelli GNicolò, Stefanizzi L, Giunchi F et al..  2021.  Metabolomics of Prostate Cancer Gleason Score in Tumor Tissue and Serum.. Mol Cancer Res. 19(3):475-484.

Brady NJ, Bagadion AM, Singh R, Conteduca V, Van Emmenis L, Arceci E, Pakula H, Carelli R, Khani F, Bakht M et al..  2021.  Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer.. Nat Commun. 12(1):3372.

Imada ELuidy, Sanchez DFernando, Dinalankara W, Vidotto T, Ebot EM, Tyekucheva S, Franco GRegina, Mucci LAnn, Loda M, Schaeffer EMatthew et al..  2021.  Transcriptional landscape of PTEN loss in primary prostate cancer.. BMC Cancer. 21(1):856.

Butler LM, Perone Y, Dehairs J, Lupien LE, de Laat V, Talebi A, Loda M, Kinlaw WB, Swinnen JV.  2020.  Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention.. Adv Drug Deliv Rev. 159:245-293.

Stopsack KH, Huang Y, Tyekucheva S, Gerke TA, Bango C, Elfandy H, Bowden M, Penney KL, Roberts TM, Parmigiani G et al..  2020.  Multiplex Immunofluorescence in Formalin-Fixed Paraffin-Embedded Tumor Tissue to Identify Single-Cell-Level PI3K Pathway Activation.. Clin Cancer Res. 26(22):5903-5913.

Crowley L, Cambuli F, Aparicio L, Shibata M, Robinson BD, Xuan S, Li W, Hibshoosh H, Loda M, Rabadan R et al..  2020.  A single-cell atlas of the mouse and human prostate reveals heterogeneity and conservation of epithelial progenitors.. Elife. 9

Elfandy H, Armenia J, Pederzoli F, Pullman E, Pertega-Gomes N, Schultz N, Viswanathan K, Vosoughi A, Blattner M, Stopsack KH et al..  2019.  Genetic and Epigenetic Determinants of Aggressiveness in Cribriform Carcinoma of the Prostate.. Mol Cancer Res. 17(2):446-456.

Labbé DP, Zadra G, Yang M, Reyes JM, Lin CY, Cacciatore S, Ebot EM, Creech AL, Giunchi F, Fiorentino M et al..  2019.  High-fat diet fuels prostate cancer progression by rewiring the metabolome and amplifying the MYC program.. Nat Commun. 10(1):4358.

Zadra G, Ribeiro CF, Chetta P, Ho Y, Cacciatore S, Gao X, Syamala S, Bango C, Photopoulos C, Huang Y et al..  2019.  Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancer.. Proc Natl Acad Sci U S A. 116(2):631-640.